Albion Financial Group UT Purchases 506 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Albion Financial Group UT boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 182.7% in the fourth quarter, HoldingsChannel reports. The firm owned 783 shares of the biopharmaceutical company’s stock after buying an additional 506 shares during the quarter. Albion Financial Group UT’s holdings in Gilead Sciences were worth $72,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Advisory Alpha LLC bought a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $260,000. XML Financial LLC purchased a new position in Gilead Sciences in the fourth quarter worth $203,000. Genesis Private Wealth LLC bought a new position in Gilead Sciences in the 4th quarter valued at $362,000. Simon Quick Advisors LLC increased its position in shares of Gilead Sciences by 24.7% during the 4th quarter. Simon Quick Advisors LLC now owns 6,120 shares of the biopharmaceutical company’s stock valued at $565,000 after purchasing an additional 1,214 shares during the last quarter. Finally, MCF Advisors LLC raised its stake in shares of Gilead Sciences by 45.2% during the 4th quarter. MCF Advisors LLC now owns 6,779 shares of the biopharmaceutical company’s stock worth $626,000 after purchasing an additional 2,111 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.1 %

Shares of GILD opened at $93.04 on Thursday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The company has a market capitalization of $115.95 billion, a P/E ratio of 1,033.78, a P/E/G ratio of 1.29 and a beta of 0.18. The firm’s 50 day simple moving average is $91.62 and its 200 day simple moving average is $84.57.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm’s revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.29 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were given a dividend of $0.77 per share. The ex-dividend date was Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.31%. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction on Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the transaction, the chief financial officer now owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares of the company’s stock, valued at $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 456,234 shares of company stock valued at $42,130,461. Corporate insiders own 0.29% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on GILD shares. Wells Fargo & Company increased their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Mizuho raised their price target on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Truist Financial upped their price objective on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research note on Friday, November 8th. JPMorgan Chase & Co. raised their target price on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Finally, The Goldman Sachs Group upped their price target on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $97.96.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.